The revamp of French drugmaker Sanofi under new chief executive Paul Hudson has filtered up to top management, with four senior figures leaving the company. The move comes shortly after Hudson ...

Sanofi CEO Paul Hudson stated: "The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios.

From new industry M&As to insights on how to recruit Gen Z talent, there’s plenty to discover in our latest pharma news round ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Sanofi (ENXTPA:SAN) has recently announced it will begin shipping Beyfortus in early Q3 2025. This move aims to support healthcare providers ahead of the RSV season. Sanofi's commitment to ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent (dupilumab), for the treatment of adult patients with bullous pemphigoid (BP ...

MONROE COUNTY, Pa. - Sanofi, maker of anti-inflammation drug Dupixent, will report third-quarter earnings Friday before the opening of U.S. markets. Paris-based Sanofi is the parent company of ...

Both organisations will advance clinical research and development planning, optimise resource allocation and establish the foundational terms for funding and access. DoH and Sanofi are collaborating ...

(RTTNews) - Sanofi S.A. (SNYNF, SNY) is speeding up the global distribution of Beyfortus (nirsevimab) to ensure healthcare providers have access well in advance of the 2025-2026 RSV season ...

76% of patients in the Dupixent trial reached ≥75% improvement in eczema severity at 24 weeks. Sanofi has tripled Beyfortus production and doubled manufacturing sites since its 2023 launch. Get ...